LKT Labs

Biochemicals for Life Science Research

Cyclovirobuxine D

Cyclovirobuxine D

Product ID C9711
Cas No. 860-79-7
Purity ≥97%
Product Unit SizeCostQuantityStock
25 mg $127.60 In stock
100 mg $317.50 In stock
500 mg $1,086.00 In stock
Bulk Quote

Quicklinks

Description

Cyclovirobuxine D is originally found in Buxus and displays cardioprotective and anticancer activities. Cyclovirobuxine inhibits the viability of breast cancer cells, inhibiting phosphorylation of Akt and mTOR and inducing autophagy. This compound also shows benefit in the treatment of heart failure but may prolong the QT interval through inhibition of human ether-a-go-go-related (hERG) K+ channel currents. Additionally, cyclovirobuxine D decreases infarct size and venous thrombus size in animal models of myocardial ischemia.

Product Info

Cas No.

860-79-7
Purity

≥97%
Formula

C26H46N2O
Formula Wt.

402.66
IUPAC Name

C26H46N2O
Synonym

Bebuxine, Cyclovirobuxine
Melting Point

219-224°C
Appearance

White crystal

Shipping and Storage

Store Temp

4°C
Ship Temp

Ambient

Downloads

MSDS

C9711 MSDS PDF
Info Sheet

C9711 Info Sheet PDF

References

Lu J, Sun D, Gao S, et al. Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells. J Pharmacol Sci. 2014;125(1):74-82. PMID: 24758922.

Yu B, Fang TH, Lü GH, et al. Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction. Fitoterapia. 2011 Sep;82(6):868-77. PMID: 21575690.

Zhao J, Wang Q, Xu J, et al. Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells. Eur J Pharmacol. 2011 Jun 25;660(2-3):259-67. PMID: 21497594.

Hu D, Liu X, Wang Y, et al. Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis. Eur J Pharmacol. 2007 Aug 13;569(1-2):103-9. PMID: 17555743.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • C6956

    Crotamiton

    Antipruritic.

    ≥98%
  • C1632

    Cefotaxime Acid

    β-lactam cephalosporin; penicillin binding pro...

    ≥91%
  • M5876

    Motesanib

    VEGFR1/2/3, PDGFR, c-Kit, RET inhibitor.

    ≥98%
  • C0374

    β-Casomorphin, human

    Peptide, casein fragment.

    ≥95%
  • T9970

    Tyrphostin AG1295

    PDGFR inhibitor.

    ≥98%
  • G5875

    Gossypol Acetic Acid

    Bcl-2, Bcl-xl, sialyl transferase inhibitor.

    ≥98%
  • Z3463

    Ziprasidone

    5-HT1A agonist, D2, 5-HT1D antagonist.

    ≥98%
  • N0062

    D,L-Naproxen

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • G3460

    Ginsenoside F1

    Triterpene saponin found in species of Panax.

    ≥98%
  • R3586

    Rivastigmine Tartrate

    AChE and BChE inhibitor.

    ≥99%
  • R2710

    Recombinant Multi-epitope Chimeric HCV Antigen

    Recombinant Multi-epitope Chimeric HCV antigen....

    ≥95%
  • R3012

    Recombinant TpN 17 protein

    Recombinant protein containing Treponema pallid...

    ≥95%
  • M1877

    Methylprednisolone

    Synthetic steroid; glucocorticoid agonist.

    ≥96%
  • J889280

    JWH 015

    Cannabinoid receptor 2 selective agonist.

    ≥98%
  • N0114

    Nadifloxacin

    Fluoroquinolone; bacterial DNA gyrase inhibitor...

    ≥98%
  • A6058

    Apoptosis Activator 2

    Apoptosis inducing agent.

    ≥98%
  • A6982

    Artesunate

    Sesquiterpene lactone derived from Artemesia.

    ≥98%
  • M1879

    Metoprolol Tartrate

    β1-adrenergic antagonist.

    ≥98%
  • A4678

    Alternariol-9-methyl Ether

    Mycotoxin produced by Alternaria; oxidative pho...

    ≥98%
  • S3346

    Silodosin

    α1A-adrenergic antagonist.

    ≥98%